ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor‐tyrosine kinase inhibitor, enhances the anti‐cancer effects of TRAIL in human esophageal squamous cell carcinoma
Fuminori Teraishi(Okayama Shoka University), Toshiyoshi Fujiwara(Okayama University)
Cited by 64
Related Papers
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer
|JCI Insight|2018|148
The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer
|Journal of Experimental & Clinical Cancer Research|2018|111